• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by LumiraDx Limited (Amendment)

    11/7/23 7:12:49 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $LMDX alert in real time by email
    SC 13D/A 1 d556492dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1 )*

     

     

    LumiraDx Limited

    (Name of Issuer)

    Common Shares, par value $0.0000028 per share

    (Title of Class of Securities)

    G5709L109

    (CUSIP Number)

    Jerome F. McAleer

    52 Nobles Close

    Grove, OX12 0NR

    United Kingdom

    +44 199 377 6060

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    November 1, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box:  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    (Continued on following pages)


    CUSIP No. G5709L109    SCHEDULE 13D   

     

      1    

      NAMES OF REPORTING PERSONS

     

      Jerome F. McAleer

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      N/A (please see Item 3)

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United Kingdom

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      15,792,205*

         8  

      SHARED VOTING POWER

     

      0

         9  

      SOLE DISPOSITIVE POWER

     

      15,792,205*

       10  

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      15,792,205*

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      9.3%**

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IN

     

    *

    Consists of 7,736,677 outstanding ordinary shares, 8,055,428 ordinary shares issuable upon the exercise of vested options and 100 common shares issuable upon the exercise of outstanding options. Each ordinary share has ten votes per share on all matters subject to the vote of the shareholders. The ordinary shares are convertible at any time into an equal number of common shares at the option of the holder thereof.

    **

    Based on (i) 154,224,500 common shares outstanding on December 31, 2022, as reported in the Issuer’s Form 20-F filed with the Securities and Exchange Commission on May 1, 2023, plus (ii) the 15,792,205 shares reported in row 11 above.    


    Item 1. Security and Issuer.

    This Amendment No. 1 to Schedule 13D (“Amendment No. 1”) amends and supplements the statement on Schedule 13D originally filed with the United States Securities and Exchange Commission (“SEC”) on August 24, 2022 (the “Original Filing”), by Jerome F. McAleer (the “Reporting Person”). The Original Filing remains in effect except to the extent that it is amended, restated or superseded by information contained in this Amendment No. 1. Capitalized terms used and not defined in this Amendment No. 1 have the meanings set forth in the Original Filing.

    Item 2. Identity and Background.

    (b) The principal business address of the Reporting Person is 52 Nobles Close, Grove, OX12 0NR, United Kingdom.

    (c) The present principal occupation of the Reporting Person is Entrepreneur. The principal business address of the Issuer is listed in Item 2(b).

    Item 4. Purpose of the Transaction.

    The Reporting Person acquired beneficial ownership of the Common Shares in his capacity as Co-Founder, Director and Chief Scientist of the Issuer. The Reporting Person resigned from his director and officer roles with the Issuer effective November 1, 2023 after concluding that, in light of the Issuer’s ongoing search for a viable long-term solution to its financial difficulties, it is in the best interests of the Issuer and its stakeholders, including its creditors, that he step down from his current roles with the Company in order to preserve his flexibility to explore all available options. The Reporting Person will continue to participate in the affairs of the Issuer through its ownership interest and the voting of his Ordinary Shares. Each Ordinary Share has ten votes per share on all matters subject to the vote of the shareholders.

    The Reporting Person, at any time, and from time to time may acquire additional Ordinary Shares or Common Shares or dispose of any or all of the Ordinary Shares or Common Shares that he owns depending upon an ongoing evaluation of his investment in the Issuer, prevailing market conditions, other investment opportunities, other investment considerations and/or other factors.

    Except as disclosed herein, the Reporting Person has no plan or proposal which relate to, or could result in, any of the matters referred to in paragraphs (b) through (j) inclusive of the instructions to Item 4 of Schedule 13D.

    The Reporting Person may, at any time and from time to time, review or reconsider his position and/or change his purpose and/or formulate plans or proposals with respect thereto.

    Item 5. Interest in Securities of the Issuer.

     

      (a)

    The Reporting Person may be deemed to beneficially own an aggregate of 15,792,205 Common Shares, representing 9.3% of the Common Shares. The aggregate number of Common Shares beneficially owned by the Reporting Person consists of 7,736,677 outstanding Ordinary Shares, 8,055,428 Ordinary Shares issuable upon the exercise of vested options, and 100 Common Shares issuable upon the exercise of vested options. Outstanding Ordinary Shares are convertible at any time into an equal number of Common Shares at the option of the holder thereof. The percentage of Common Shares beneficially owned by the Reporting Person is based on 154,224,500 Common Shares outstanding on December 31, 2022, as reported in the Issuer’s Form 20-F filed with the SEC on May 1, 2023. Pursuant to Rule 13d-3(d)(i)(1), any percentage ownership of Common Stock disclosed herein reflects the percentage ownership that the Reporting Person would hold if they exercised their rights to acquire Common Shares, without any other person exercising similar rights. These percentages should not be taken to reflect the Reporting Person’s proportion of economic interest or voting power in the Issuer.

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    Founder Options

    On January 15, 2021, the Issuer granted the following “founder options” over ordinary shares to the Reporting Person: (i) a fully vested option over 5,235,851 ordinary shares with an exercise price of $16.96 per ordinary share and (ii) following shareholder approval obtained on February 1, 2021, an additional option over 2,819,577 ordinary shares with an exercise price of $17.05 per ordinary share, vesting over a two-year period subject to the satisfaction of certain performance conditions.

    Vested stock options will expire on the three-month anniversary of the Reporting Person’s resignation date.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: November 7, 2023

     

    JEROME F. MCALEER
    By:  

    /s/ Jerome F. McAleer

    Name:   Jerome F. McAleer
    Get the next $LMDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LMDX

    DatePrice TargetRatingAnalyst
    3/11/2022$13.00 → $9.00Outperform
    Raymond James
    11/15/2021$20.00Outperform
    Evercore ISI Group
    10/27/2021$12.00Buy
    BTIG Research
    10/25/2021$13.00Outperform
    Raymond James
    More analyst ratings

    $LMDX
    SEC Filings

    See more
    • SEC Form 6-K filed by LumiraDx Limited

      6-K - LumiraDx Ltd (0001685428) (Filer)

      2/6/24 4:34:15 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 6-K filed by LumiraDx Limited

      6-K - LumiraDx Ltd (0001685428) (Filer)

      12/29/23 4:26:15 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 6-K filed by LumiraDx Limited

      6-K - LumiraDx Ltd (0001685428) (Filer)

      12/8/23 7:15:38 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LMDX
    Leadership Updates

    Live Leadership Updates

    See more
    • LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th

      LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX)(the "Company") today announced that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company's failure to maintain compliance with Nasdaq's continued listing standards. As previously disclosed, on October 24, 2023, the Company received a notice from Nasdaq's Listing Qualifications Department (the "Staff") stating that the Company's securities were subject to delisting from The Nasdaq Global Market due to a failure to maintain compliance with the minimum bid price requirement of Nasd

      1/5/24 5:45:23 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche

      LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX) (the "Company"), a next generation point of care diagnostics company, announced today the appointment of joint administrators for two of its subsidiaries. The administrators have signed a definitive agreement to sell certain companies of the LumiraDx group related to LumiraDx's innovative point of care technology to Roche. The Company announced today that Andrew Johnson, Lisa Rickelton and Lindsay Hallam of FTI Consulting LLP have been appointed as joint administrators of two of its subsidiaries, LumiraDx Group Limited and LumiraDx International Limited, which together hold substantially all of the assets of the Lumi

      12/29/23 4:15:50 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LMDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th

      LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX)(the "Company") today announced that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company's failure to maintain compliance with Nasdaq's continued listing standards. As previously disclosed, on October 24, 2023, the Company received a notice from Nasdaq's Listing Qualifications Department (the "Staff") stating that the Company's securities were subject to delisting from The Nasdaq Global Market due to a failure to maintain compliance with the minimum bid price requirement of Nasd

      1/5/24 5:45:23 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche

      LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX) (the "Company"), a next generation point of care diagnostics company, announced today the appointment of joint administrators for two of its subsidiaries. The administrators have signed a definitive agreement to sell certain companies of the LumiraDx group related to LumiraDx's innovative point of care technology to Roche. The Company announced today that Andrew Johnson, Lisa Rickelton and Lindsay Hallam of FTI Consulting LLP have been appointed as joint administrators of two of its subsidiaries, LumiraDx Group Limited and LumiraDx International Limited, which together hold substantially all of the assets of the Lumi

      12/29/23 4:15:50 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal

      LONDON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- On October 24, 2023, LumiraDx Limited (NASDAQ:LMDX)(the "Company") received a notice ("Notice") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") stating that on April 21, 2023, the Staff had notified the Company that the bid price of its listed securities had closed at less than $US1.00 per share over the previous 30 consecutive business days, and, as a result, did not comply with Listing Rule 5450(a)(1) (the "Minimum Bid Requirement"). Therefore, in accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until October 18, 2023, to regain compliance with the Minimu

      10/27/23 4:45:02 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LMDX
    Financials

    Live finance-specific insights

    See more
    • LumiraDx Reports Second Quarter 2023 Results

      LONDON, Aug. 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its second quarter ended June 30, 2023. Second quarter 2023 revenues of $21.0 millionSubmitted First 510(k) Application to the U.S. Food and Drug Administration (FDA) for 5-minute COVID Ultra testSubmitted COVID/Flu combo test for FDA Emergency Use Authorization (EUA) as part of the NIH's Independent Test Assessment (ITAP) programMore than 1,500 new instruments shipped in Q2, primarily to U.S. pharmacy locations to expand testing capacity for the upcoming respiratory season Ron Zwanziger, Chairman and CEO of LumiraD

      8/24/23 7:45:00 AM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24

      LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited  (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 24, 2023. On the day of the release, LumiraDx will host a conference call and webcast at 8:30 AM Eastern Time to review the financial results and business highlights.    LumiraDx Second Quarter 2023 Financial Results Conference Call  Date:Thursday, August 24, 2023Time:8:30 AM Eastern Time   Live Call/Webcast:   Register to join by phone here.  View webcast: https://investors.lumiradx.com/news-and-events/investor-calendar    A replay of the webcast will be available on the Inv

      8/16/23 4:30:00 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • LumiraDx Reports First Quarter 2023 Results

      LONDON, May 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its first quarter ended March 31, 2023. First quarter 2023 revenues of $22.2 million.Cost reduction programs implemented across the global organization resulting in declining operating losses.US Clinical Studies for first 510K submission completed.More than 100 customers in the first full launch quarter for the world's first quantitative finger stick NT-proBNP assay. Ron Zwanziger, Chairman and CEO of LumiraDx, stated, "Our transition to non-COVID is beginning to develop, especially with the commercial launches of HbA1c

      5/16/23 7:45:00 AM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LMDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James reiterated coverage on LumiraDx with a new price target

      Raymond James reiterated coverage of LumiraDx with a rating of Outperform and set a new price target of $9.00 from $13.00 previously

      3/11/22 7:22:18 AM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Evercore ISI Group initiated coverage on LumiraDx with a new price target

      Evercore ISI Group initiated coverage of LumiraDx with a rating of Outperform and set a new price target of $20.00

      11/15/21 8:56:20 AM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • BTIG Research initiated coverage on LumiraDx with a new price target

      BTIG Research initiated coverage of LumiraDx with a rating of Buy and set a new price target of $12.00

      10/27/21 8:35:45 AM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LMDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)

      SC 13G/A - LumiraDx Ltd (0001685428) (Subject)

      2/12/24 4:06:57 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)

      SC 13G/A - LumiraDx Ltd (0001685428) (Subject)

      2/9/24 4:16:20 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13D/A filed by LumiraDx Limited (Amendment)

      SC 13D/A - LumiraDx Ltd (0001685428) (Subject)

      12/29/23 1:52:49 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care